ARIA stands for amyloid-related imaging abnormalities. It is a possible side effect of certain Alzheimer's treatments that can cause swelling or small areas of bleeding in the brain. Doctors usually detect ARIA with MRI brain scans. Many cases cause no symptoms and improve over time, but some need treatment to be paused or stopped because serious complications can occur.
ARIA is especially important for people receiving newer Alzheimer's medicines that remove amyloid, a protein that builds up in the brain. Understanding what ARIA means, how doctors monitor it, and what happens when it develops can help patients and families make informed treatment decisions.
How Is ARIA Connected to Alzheimer's Medicines?
Some newer Alzheimer's treatments work by targeting beta-amyloid, a protein that forms plaques in the brain. These medicines are called anti-amyloid antibodies. They help remove amyloid deposits and can modestly slow worsening memory, thinking, and daily functioning in people with early Alzheimer's disease.
ARIA is a recognized safety concern with these medicines. Changes involving brain swelling or small blood vessels may appear during treatment. These changes are often visible on MRI scans before a person notices anything unusual.
According to Mayo Clinic, lecanemab (Leqembi) and donanemab (Kisunla) are anti-amyloid medicines used for people with mild cognitive impairment or mild dementia due to Alzheimer's disease. They reduce amyloid in the brain and modestly slow cognitive decline, but their potential side effects require careful monitoring.
ARIA is not the same as the memory loss or thinking difficulties caused by Alzheimer's disease itself. It is an imaging finding that may develop during treatment, although some amyloid-related imaging changes can also occur without these medicines.
What Are the Two Types of ARIA?
Doctors divide ARIA into two main types based on what appears on a brain MRI. A person may develop one type or both together.
ARIA-E: Swelling or Fluid in the Brain
ARIA-E refers to amyloid-related imaging abnormalities with edema. Edema means swelling caused by excess fluid. With ARIA-E, MRI scans may show swelling in parts of the brain or fluid collecting within spaces along its surface.
Many people with ARIA-E experience no symptoms. When symptoms occur, they may include headaches, confusion, dizziness, or changes in vision.
ARIA-E often improves after treatment is interrupted, although it can sometimes progress after first being detected. More serious cases may affect neurological function and require urgent medical care.
ARIA-H: Small Areas of Bleeding
ARIA-H refers to amyloid-related imaging abnormalities with hemosiderin deposition. Hemosiderin is an iron-containing substance left behind when blood breaks down.
ARIA-H includes two important MRI findings:
- Cerebral microhemorrhages: Very small areas of bleeding within brain tissue.
- Superficial siderosis: Blood-breakdown deposits along the surface of the brain.
Unlike the swelling associated with ARIA-E, some signs of previous bleeding may remain visible on MRI even after the active problem has stabilized.
ARIA-H does not always cause noticeable symptoms. However, larger brain hemorrhages are a serious potential complication of anti-amyloid treatment and must be considered separately from small MRI-detected microhemorrhages.
What Symptoms Can ARIA Cause?
Most ARIA events are detected through imaging rather than symptoms. Still, patients and caregivers should recognize changes that may require prompt assessment.
Possible symptoms associated with ARIA include:
- Headaches that are new, unusual, or worsening
- Increased confusion or unexpected changes in thinking
- Dizziness or difficulty maintaining balance
- Changes in vision
- Nausea
- Difficulty walking normally
- Weakness or difficulty speaking
- Seizures in serious cases
These symptoms can have several possible causes. Their presence does not establish that someone has ARIA, but new neurological symptoms during anti-amyloid treatment should never be ignored.
The U.S. Food and Drug Administration (FDA) advises patients taking lecanemab to contact their healthcare professional or seek emergency care immediately if symptoms suggesting ARIA develop. The agency also emphasizes that brain swelling can worsen after it is first identified.
Sudden weakness, difficulty speaking, seizures, severe confusion, or other abrupt neurological changes require emergency evaluation. ARIA-related symptoms can sometimes resemble a stroke, so patients and caregivers should tell emergency clinicians about any anti-amyloid treatment being received.
Who Has a Higher Risk of Developing ARIA?
Not everyone receiving anti-amyloid treatment develops ARIA. Doctors consider several factors before recommending therapy and throughout the treatment period.
- APOE ε4 genetic status: People who inherit two copies of the APOE ε4 gene variant have a higher risk of ARIA, including serious or symptomatic events, than people with one or no copies.
- Existing MRI abnormalities: Previous brain microhemorrhages or superficial siderosis may indicate increased risk during treatment.
- Cerebral amyloid angiopathy: Amyloid deposits in brain blood vessel walls can be associated with bleeding-related imaging abnormalities.
- Medicines affecting blood clotting: Anticoagulants require particular caution because of concerns about intracerebral hemorrhage.
- Early treatment period: ARIA frequently develops during the earlier stages of anti-amyloid treatment, making scheduled monitoring particularly important.
Before starting treatment, a specialist may recommend APOE genetic testing to help explain the possible risks. The result does not predict with certainty whether ARIA will occur, but it can contribute to a more informed discussion.
Clinicians also review previous brain scans, current medicines, medical history, and other factors affecting bleeding risk. Patients should not stop prescribed anticoagulants or other medications without medical guidance.
How Do Doctors Check for ARIA?
Magnetic resonance imaging, or MRI, is the main way doctors identify and monitor ARIA. MRI scans can detect swelling and small bleeding-related changes that may not produce symptoms.
Brain MRI Before Treatment
Patients being considered for anti-amyloid treatment generally undergo a brain MRI before their first dose.
This scan helps doctors identify existing abnormalities that could affect treatment safety and provides a baseline for comparison with future scans.
The specialist also confirms whether the patient meets the eligibility criteria for the medicine, including evidence of amyloid associated with Alzheimer's disease.
Scheduled MRI Scans During Treatment
Repeat imaging is an important part of anti-amyloid therapy. The exact schedule depends on the medicine and its current prescribing information.
For lecanemab given through intravenous infusions, the FDA recommends MRI monitoring before the third, fifth, seventh, and fourteenth infusions, in addition to the pretreatment scan. The earlier third-infusion MRI was recommended to help identify potentially serious swelling sooner.
Donanemab has its own MRI monitoring requirements, so the schedule should not be assumed to be identical for every anti-amyloid medicine.
Extra MRI scans may be needed when symptoms arise or when a previous scan has shown ARIA. Doctors assess both the MRI findings and the person's clinical condition before deciding whether treatment can continue.
What Happens if ARIA Is Found on an MRI?
Finding ARIA does not automatically mean that Alzheimer's treatment must be stopped permanently. The next step depends on the type of abnormality, its extent, whether symptoms are present, and whether the changes are getting worse.
A neurologist or another appropriately trained specialist may review the scan, perform a clinical assessment, compare the findings with earlier images, and decide whether more frequent monitoring or a treatment change is necessary.
Option 1: Continue Treatment With Close Monitoring
Some patients with limited MRI abnormalities and no symptoms may be able to continue treatment under careful supervision, depending on the medicine and the severity of the imaging findings.
This decision follows drug-specific safety recommendations rather than a general rule that all symptom-free ARIA is harmless.
Option 2: Temporarily Pause the Alzheimer's Medicine
When ARIA is more extensive or causes symptoms, doctors may temporarily withhold anti-amyloid treatment.
During the pause, additional MRI scans help determine whether swelling has resolved or bleeding-related changes have stabilized. The specialist also checks whether neurological symptoms have improved.
Treatment may sometimes restart when the required safety conditions are met. The decision depends on the particular medicine, MRI findings, symptom recovery, and the patient's overall treatment goals.
Option 3: Stop the Medicine Permanently
Some ARIA events make continuing treatment too risky. Permanent discontinuation may be considered when serious neurological complications occur, when bleeding-related findings exceed drug-specific safety limits, or when the treating specialist determines that the risks outweigh the expected benefits.
The decision is individualized. Families should understand why treatment is being discontinued and what other care options remain available.
Option 4: Hospital Care for Serious ARIA
Severe ARIA may require treatment in a hospital, particularly when seizures, significant swelling, or other major neurological problems develop.
Hospital treatment focuses on the patient's neurological condition and complications. Management can include specialist monitoring, repeat imaging, seizure treatment when needed, and other supportive measures. Specialists may consider additional treatment for severe swelling in selected situations.
There is no single medicine that is routinely required for every case of ARIA. Management is based on the clinical findings and severity of the event.
Does ARIA Go Away? What Are the Results?
Many cases of ARIA improve over time, especially when swelling is limited and recognized early. However, outcomes depend on whether the abnormality involves swelling, bleeding, or both.
With ARIA-E, swelling often resolves on follow-up MRI scans. Symptoms, if present, may also improve. More serious cases can take longer and may require changes to treatment.
With ARIA-H, the situation is different. Small bleeding-related deposits can remain visible on MRI even after there is no ongoing bleeding. Doctors therefore look for stability rather than expecting every MRI finding to disappear.
The FDA's lecanemab clinical trial summary reports that ARIA-E occurred in approximately 13% of participants taking lecanemab, compared with 2% receiving placebo. ARIA-H occurred in approximately 14% of treated participants, compared with 8% receiving placebo. These figures come from a specific trial and should not be treated as an individual's predicted risk.
Most participants who developed ARIA did not experience symptoms. Nevertheless, rare serious outcomes, including life-threatening brain swelling and hemorrhage, have been reported with anti-amyloid medicines.
In practice, successful ARIA management may mean that swelling resolves, neurological symptoms improve, no new bleeding develops, and the person can safely continue with an appropriate treatment plan. In other cases, the safest outcome is to discontinue anti-amyloid therapy.
Can Alzheimer's Treatment Still Work if ARIA Develops?
ARIA does not necessarily mean that the Alzheimer's medicine has failed. ARIA is a safety-related complication, while the intended benefit of anti-amyloid treatment is to slow the progression of cognitive and functional decline.
These medicines do not reverse Alzheimer's disease or restore lost memory. Their benefit is generally measured by how much they slow worsening over time compared with untreated progression in clinical trials.
If treatment must be paused because of ARIA, doctors reassess whether restarting offers a reasonable balance between potential benefit and future risk. A temporary interruption does not guarantee that the medicine will be safe to resume.
There is also no reason to interpret ARIA as proof that amyloid removal is working better. It is an adverse imaging finding, not a measure of treatment success.
How Do Lecanemab and Donanemab Compare for ARIA Risk?
Lecanemab and donanemab both target amyloid and can cause ARIA, but their dosing schedules, clinical trial findings, and monitoring instructions are not identical.
Clinical studies of both medicines have reported brain swelling and bleeding-related imaging abnormalities. The frequency of ARIA varies according to the drug, study population, dosing regimen, and risk factors.
The Alzheimer's Association explains that lecanemab slows cognitive and functional decline in people with early Alzheimer's disease and identifies ARIA among its important side effects. Donanemab is another approved anti-amyloid treatment with similar safety concerns.
Directly comparing percentages from separate clinical trials can be misleading because the studies may differ in how participants were selected, treated, and monitored.
For someone deciding between these medicines, an Alzheimer's specialist can explain how individual MRI findings, APOE status, other medications, and treatment goals affect the choice.
What Should Patients and Caregivers Ask Before Starting Treatment?
Understanding ARIA risk before the first dose can make ongoing care easier to manage. Patients and caregivers can discuss practical questions with the treatment team, including:
- Does the pretreatment MRI show any findings that increase the risk of ARIA?
- Would APOE genetic testing help clarify treatment risks?
- Which MRI appointments will be required during treatment?
- What symptoms should prompt urgent contact with the care team?
- Could any current medications increase the risk of brain bleeding?
- What would happen if an MRI showed swelling or a new microhemorrhage?
- Under what circumstances could treatment restart after a pause?
It is useful for caregivers to know the medicine's name and dosing schedule, especially when the patient has difficulty remembering appointments or describing symptoms.
Patients receiving anti-amyloid treatment should also tell emergency clinicians about their medication if they develop sudden neurological symptoms. This information may affect how clinicians evaluate possible stroke or bleeding.
Balancing ARIA Risks With Alzheimer's Treatment Benefits
Anti-amyloid medicines represent an important development in early Alzheimer's treatment because they can slow aspects of disease progression. However, their benefits need to be weighed against the possibility of ARIA, the burden of repeated monitoring, and the patient's overall health.
Someone with concerning pretreatment MRI findings or additional bleeding risks may require a different discussion from someone without those factors.
The goal is not simply to avoid every possible side effect. It is to choose treatment that offers a reasonable chance of meaningful benefit while maintaining appropriate safeguards.
For many people, ARIA is a manageable imaging finding that improves with monitoring or temporary treatment changes. For a smaller number, it can cause serious complications. Regular MRI scans, clear communication, and timely response to new symptoms are essential parts of safe anti-amyloid therapy.
This information is intended for patient and caregiver education and does not replace individualized advice from an Alzheimer's specialist or other qualified healthcare professional.